Eagle Asset Management Inc. Has $20.27 Million Stock Position in TransMedics Group, Inc. (NASDAQ:TMDX)

Eagle Asset Management Inc. lowered its stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 16.3% during the 3rd quarter, Holdings Channel.com reports. The firm owned 129,094 shares of the company’s stock after selling 25,214 shares during the quarter. Eagle Asset Management Inc.’s holdings in TransMedics Group were worth $20,268,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the stock. Charles Schwab Investment Management Inc. raised its holdings in shares of TransMedics Group by 2.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 271,694 shares of the company’s stock valued at $42,656,000 after purchasing an additional 6,634 shares during the period. Intech Investment Management LLC acquired a new position in shares of TransMedics Group during the third quarter valued at about $2,167,000. Connor Clark & Lunn Investment Management Ltd. raised its holdings in shares of TransMedics Group by 665.1% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 74,625 shares of the company’s stock valued at $11,716,000 after purchasing an additional 64,872 shares during the period. B. Metzler seel. Sohn & Co. Holding AG acquired a new stake in shares of TransMedics Group in the 3rd quarter worth about $1,059,000. Finally, Pathstone Holdings LLC raised its holdings in shares of TransMedics Group by 4.9% in the 3rd quarter. Pathstone Holdings LLC now owns 26,381 shares of the company’s stock worth $4,142,000 after acquiring an additional 1,231 shares during the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on TMDX. Needham & Company LLC restated a “hold” rating and issued a $109.00 target price on shares of TransMedics Group in a report on Friday. Baird R W raised shares of TransMedics Group to a “strong-buy” rating in a report on Tuesday, September 24th. Robert W. Baird cut their price target on shares of TransMedics Group from $200.00 to $150.00 and set an “outperform” rating for the company in a report on Tuesday, October 29th. Stephens raised their price target on shares of TransMedics Group from $151.00 to $178.00 and gave the company an “overweight” rating in a report on Friday, August 2nd. Finally, Oppenheimer cut their price target on shares of TransMedics Group from $200.00 to $125.00 and set an “outperform” rating for the company in a report on Tuesday, October 29th. Two research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, TransMedics Group currently has a consensus rating of “Moderate Buy” and a consensus price target of $131.80.

TransMedics Group Stock Performance

TransMedics Group stock opened at $76.04 on Friday. The stock has a market cap of $2.55 billion, a P/E ratio of 80.89 and a beta of 2.08. The firm’s fifty day moving average price is $120.68 and its 200-day moving average price is $138.09. TransMedics Group, Inc. has a fifty-two week low of $67.77 and a fifty-two week high of $177.37. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20.

TransMedics Group (NASDAQ:TMDX) last issued its earnings results on Monday, October 28th. The company reported $0.12 EPS for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). The business had revenue of $108.76 million during the quarter, compared to analysts’ expectations of $115.00 million. TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. TransMedics Group’s revenue for the quarter was up 63.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.12) EPS. On average, equities research analysts expect that TransMedics Group, Inc. will post 1 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, insider Nicholas Corcoran sold 10,000 shares of the company’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $176.02, for a total transaction of $1,760,200.00. Following the completion of the transaction, the insider now directly owns 21,105 shares of the company’s stock, valued at approximately $3,714,902.10. This represents a 32.15 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Edward M. Basile sold 6,750 shares of the company’s stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $83.55, for a total transaction of $563,962.50. Following the transaction, the director now directly owns 732 shares of the company’s stock, valued at approximately $61,158.60. This trade represents a 90.22 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 36,958 shares of company stock worth $5,230,528 in the last 90 days. 7.00% of the stock is owned by company insiders.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.